ArticleFrontiers in pharmacology2026
Determining the ED90 of prophylactic phenylephrine and norepinephrine infusions for higher blood pressure target maintenance during cesarean delivery: a randomized sequential allocation trial.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06158048 (ED90 of Norepinephrine and Phenylephrine Infusions for Preventing Postspinal Anesthesia Hypotension Under Intensive Treatment During Cesarean Section), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ED90 of Norepinephrine and Phenylephrine Infusions for Preventing Postspinal Anesthesia Hypotension Under Intensive Treatment During Cesarean Section
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The international consensus on vasopressors for managing hypotension emphasizes maintaining maternal systolic blood pressure (SBP) during cesarean delivery greater than 90% of the baseline and not below 80%. This study was to determine the ED90 values of prophylactic norepinephrine and phenylephrine infusions under higher blood pressure management target of maintaining maternal SBP at greater than 90% of the baseline. Method: Sixty patients aged 18-45 years, who were scheduled to undergo cesarean delivery under spinal anesthesia, were randomly assigned to the norepinephrine group and the phenylephrine group. The first patients in each group were administered prophylactic infusion rates of 0.05 and 0.5 μg/kg/min, respectively. Effectiveness was determined based on whether the current vasopressor infusion dose could achieve the predefined target for maternal SBP management at greater than 90% of the baseline prior to fetal delivery. Subsequently, the vasopressor infusion rate was adjusted incrementally or decrementally by 0.01 and 0.1 μg/kg/min as needed. Additionally, maternal adverse events and neonatal outcomes were systematically recorded and analyzed. Results: Through isotonic regression analysis, the ED90 values for prophylactic norepinephrine and phenylephrine infusions under a higher blood pressure management target were estimated to be 0.140 μg/kg/min (95% CI: 0.133-0.147) and 1.280 μg/kg/min (95% CI: 1.180-1.380), respectively. There was no statistically significant difference in the incidence of adverse events or neonatal outcomes between groups. Conclusion: When the target was established to maintain the blood pressure of patients at greater than 90% of the baseline prior to delivery in patients undergoing cesarean delivery, the prophylactic infusion rates for norepinephrine and phenylephrine were determined to be 0.140 and 1.280 μg/kg/min, respectively. Clinical Trial Registration: Clinicaltrials.gov, NCT06158048.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.